Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD. Key points to consider: • The opportunity focuses on translational bioinformatics and experimental approaches for Alzheimer's disease and related dementias. • It supports preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions. • The award ceiling is $1,000,000. • Eligible applicants include various organizations such as county governments, native American tribal governments, non-profits, and for-profit organizations. • The submission deadline is May 07, 2028.